"Canada is the only Western country without a rare disease framework. There is no official designation or recognition of rare diseases in Canada, which is a…
In Conversation
"Poland must move towards having a more patient-centric approach of healthcare, and we want to be part of this movement."
"Our weakest link is the industry-experienced drug developers and management teams. We need many more of the serial entrepreneur-type that loves to build and sell companies…
"We should be very established in Switzerland and Austria soon and work with new solutions and satisfied customers."
"In Tunisia, we strive to be pioneer in the immunology field, but most importantly we want to play an active role in the development of Tunisia’s…
"Canada has traditionally been a very important market for Lundbeck but recent changes to the market access system in terms of both Health Technology Assessment (HTA)…
"Based on our experience, the most prevalent disease types are within the oncology and cardiology therapeutic areas."
"Poland remains the largest clinical trials market in CEE – however - both patient participation and site penetration rates indicate a potential for growth."
"The biotech industry is very important for the innovation-oriented development of Brazil, our country should definitely allocate more resources to the dawn of this sector."
The senior management strongly believes that Canada is an important country for Dr. Reddy’s and certainly has the potential to become one-tenth of the US business…
"Novartis’ mantra is to either be first- or best-in-class. We are not going to introduce a ‘me, too’ drug."
"Attaining our financial objectives also lies in the recruitment of the best talents available."
